

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application No. 09/928,175

Filing Date: August 10, 2001

First Named Inventor Paszty et al.

Group Art Unit 1645-1647

Examiner Name J. Schorvason

Attorney Docket No. 00-1229

**U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | U.S. Patent Document |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
|                    |                       | Number               | Kind Code <sup>2</sup> (if known) |   |  |   |
|                    |                       |                      |                                   |   |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document |                     |                                   | Name of Patentee or Applicant of Cited Document            | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|--|--|---|----------------|
|                    |                       | Office <sup>3</sup>     | Number <sup>4</sup> | Kind Code <sup>5</sup> (if known) |  |  |   |                |
| SS                 |                       | WO                      | 99/48921            | A                                 | Board of Trustees of the Leland Stanford Junior University | 09-30-99   |   |                |
|                    |                       | WO                      | 99/15660            | A1                                | Merck & Co., Inc.  | 04-01-99   |   |                |
|                    |                       | WO                      | 99/15545            | A1                                | Merck & Co., Inc.  | 04-1-99  |   |                |
|                    |                       | WO                      | 01/36471            | A2                                | Arena Pharmaceuticals, Inc.                                |  |   |                |
|                    |                       | WO                      | 01/68858            | A2                                | Pharmacia & Upjohn Company                                 | 09-20-01   |   |                |
|                    |                       | WO                      | 01/88127            | A2                                | Bayer Aktiengesellschaft                                   | 11-22-01   |   |                |
|                    |                       | WO                      | 02/14489            | A2                                | Amgen, Inc.  | 02-21-02   |   |                |
|                    |                       | EP                      | 0950711             | A2                                | Akzo Novel N.V.  | 10-20-99   |   |                |


|                    |                      |                 |         |
|--------------------|----------------------|-----------------|---------|
| Examiner Signature | <i>J. Schorvason</i> | Date Considered | 2/15/04 |
|--------------------|----------------------|-----------------|---------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC, 20231

Substitute for form 1449A/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

|                      |                 |
|----------------------|-----------------|
| Application No.      | 09/928,175      |
| Filing Date:         | August 10, 2001 |
| First Named Inventor | Paszty et al.   |
| Group Art Unit       | 1045-1647       |
| Examiner Name        | J. Seharaseyon. |
| Attorney Docket No.  | 00-1229         |

Sheet 2 of 2

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. 1 | Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T <sup>2</sup> |
|--------------------|------------|---|----------------|
| JS                 |            | DUFAU et al., "The Luteinizing Hormone Receptor", Annu. Rev. Physiol., 1998, 60:461-96.   |                |
|                    |            | HSU et al., "Characterization of Two LGR Genes Homologous to Gonadotropin and Thyrotropin Receptors with Extracellular Leucine-Rich Repeats and a G Protein-Coupled, Seven-Transmembrane Region", Mol. Endocrinol., 1998, 12:1830-45.                     |                |
|                    |            | OSUGA et al., "Derivation of Functional Antagonists Using N-Terminal Extracellular Domain of Gonadotropin and Thyrotropin Receptors", 1997, Mol. Endocrinol. 11:1659-68.  |                |
|                    |            | MCDONALD et al., "Identification and Cloning of a Orphan G Protein-Coupled Receptor of the Glycoprotein Hormone Receptor Subfamily" Biochem. Biophys. Res. Commun. 1998, 247:266-70.  |                |
|                    |            | HSU et al., "The Three Subfamilies of Leucine-Rich Repeat-Containing G Protein-Coupled Receptors (LGR): Identification of LGR6 and LGR7 and the Signaling Mechanism for LGR7", 2000, Molecular Endocrinology 14(8): 1257-1271.                            |                |
|                    |            | OVERBEEK et al., "A Transgenic Insertion Causing Cryptorchidism in Mice", 2001, Genesis the Journal of Genetics and Development, 30:26-35.  |                |
|                    |            | AGOULNIK and GORLOV, "Cloning Great-G Protein-Coupled Receptor Affecting Testicular Descent", American Journal of Human Genetics, 2001 69(4 Supplement):218.  |                |
|                    |            | Accession No. AC077689, Mus Musculus Strain C57BL6/J Chromosome 5 RP23-301H20   |                |
|                    |            | HSU et al. "Activation of Orphan Receptors by the Hormone Relaxin", 2002, Science vol 295 671-674   |                |
|                    |            | Accession No. AF346501, Mus Musculus G Protein Coupled Receptor Affecting Testicular descent (Great) mRNA, complete cds.  |                |

RECEIVED  
JUN 10 2002  
TECH CENTER 1600/2900

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. \* Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231